Novartis (Singapore) Pte Ltd v Bristol-Myers Squibb
Pharma Co [2017] SGHC 322
I. Introduction
In the recent case of Novartis (Singapore) Pte Ltd v
Bristol-Myers Squibb Pharma Co [2017] SGHC 322, the
Singapore High Court addressed, for the first time, key procedural
issues associated with corrections to patent forms and priority
data, as well as corrections to the Singapore Patents Register (the
"Register").
II. Background
The respondent, Bristol-Myers Squibb Pharma Co
("BMS"), is the proprietor of 5 patents
("BMS' patents") in respect of the
active pharmaceutical ingredient Efavirenz, namely, Singapore
Patent Nos. SG 77853, SG 134977,
SG 111980, and SG 111981 (the
"SG 77853 Patent Family", comprising the
parent application SG 77853 and the divisional applications SG
134977, SG 111980, and SG 111981), and Singapore Patent No.
SG 76157.
